South Korean Firms Ranked in Top Asia-Pacific Deals
Three South Korean pharmaceutical companies secured spots among the most influential deals in the Asia-Pacific region for 2026.
Updated on Oct. 5, 2026 in Healthcare
Live Poll
Should the public trust large-scale pharmaceutical mergers and technology deals to lower long-term drug costs?
Samsung Biologics, SK Biopharmaceuticals, and Hanmi Pharmaceutical were named among the top 10 most influential Asia-Pacific pharmaceutical deals of 2026. Rankings were determined by Biopharma APAC based on strategic influence and transaction capital.
Why it matters
The rankings highlight the growing strategic impact of South Korean firms in the global pharmaceutical landscape. These deals demonstrate significant shifts in capital allocation and technological transfer within the regional industry.
Seven technology transfer and licensing deals reached $54.4 billion in total value, with $4.5 billion in confirmed payments. Additionally, three major M&A transactions among the top 10 ranked deals totaled approximately $16 billion in fully confirmed capital.
The players
Samsung Biologics
This major South Korean contract development and manufacturing organization ranked 6th for its $1.8 billion acquisition of PolyPeptide Group.
SK Biopharmaceuticals
This firm placed 7th following its $795 million licensing agreement for an epilepsy drug candidate from Biohaven.
Hanmi Pharmaceutical
The company ranked 9th after entering a $2.3 billion technology transfer agreement with Genentech.
The details
Evaluations covered transactions from January to September 2026 and excluded venture investment rounds. Firms were scored out of 100 on metrics including market impact, symbolism, and the ratio of confirmed to conditional capital.
Timeline
January 2026 - September 2026: Period evaluated for the deal rankings.
July 2026: Samsung Biologics announced plans to acquire PolyPeptide Group.
September 2026: Novartis signed a contract with Alteogen.
Market Landscape
This story provides the specific ranking results from the 2026 Biopharma APAC annual deal influence index. These rankings quantify the competitive shift toward Asian market consolidation and the strategic importance of technology transfers in the modern pharmaceutical era.
These massive multi-billion dollar deals signal a change in the R&D landscape that may accelerate the development of new treatments and specialized medications. Consumers should expect long-term shifts in drug availability as these partnerships integrate new technology into the supply chain.
The takeaway
The rise of South Korean firms in global rankings underscores the increasing centralization of pharmaceutical R&D in the Asia-Pacific region. Investors and stakeholders should monitor the execution of these high-value contracts as they transition from conditional agreements to market-ready products.
Further reading
For broader trends in the industry, explore our Healthcare section.
Live Poll
Should the public trust large-scale pharmaceutical mergers and technology deals to lower long-term drug costs?
